Delivery Order SPE2DB22D3301-SPE2DB25FZ0LK
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $7,652.27 and is scheduled for completion by September 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $10,098.59, represents a competitive award with no set-aside designation and is scheduled for completion by September 11, 2025. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat autoimmune conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,265.90 and is set to complete by August 13, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Humira (cf) Pen 40 mg/0.4 mls, a pharmaceutical product used primarily for the treatment of inflammatory conditions. This firm fixed price delivery order, valued at $1,510.60, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. This firm fixed-price delivery order, valued at $11,878.23, represents a non-competitive set-aside award and is scheduled for completion by September 16, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in treating autoimmune conditions. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,156.39 and is scheduled for completion by September 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a $71,310.77 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of inflammatory conditions. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $7,865.76, represents a non-set-aside competitive award and is scheduled for completion by August 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA(CF) Pen 80 mg/0.8 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, valued at $1,453.31, represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The award was made through open competition with no set-aside designation,...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0LKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs and other federal healthcare systems worldwide. The company's federal contract portfolio demonstrates consistent capability to fulfill diverse medical supply requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and specialized medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/3/25 |